Inhibikase Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused following results from the Phase 2 trial. The firm cites the company’s decision to halt further development of risvodetinib for the downgrade.